Palvella Therapeutics (PVLA) Assets Average (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Assets Average data on file, last reported at $161.7 million in Q1 2026.

• On a quarterly basis, Assets Average rose 92.83% year-over-year to $161.7 million in Q1 2026; TTM through Mar 2026 was $161.7 million, a 92.83% increase from a year earlier, with the FY2025 full-year figure at $73.9 million, up 54.3% from the prior year.
• Assets Average for Q1 2026 stood at $161.7 million, up from $63.2 million in the prior quarter.
• Over the last five years, Assets Average for PVLA reached as high as $161.7 million in Q1 2026 and fell as low as $18.5 million in Q1 2024.
• Historically, Assets Average has averaged $78.5 million across 5 years, with a median of $76.6 million in 2025.
• Across the five-year window, Assets Average tumbled 79.16% in 2024 and soared 352.62% in 2025, its largest moves.
• Year by year, Assets Average stood at $97.3 million in 2022, then slumped by 65.62% to $33.5 million in 2023, then soared by 62.51% to $54.4 million in 2024, then climbed by 16.31% to $63.2 million in 2025, then jumped by 155.6% to $161.7 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $161.7 million in Q1 2026, $63.2 million in Q4 2025, and $70.3 million in Q3 2025.